🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

442 results for “Institut” Clear

  1. Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  2. URSODEOXYCHOLIC ACID

    The George Institute

    Hepatorenal polycystic diseases

    phase 2 small molecule active

    1 trial

  3. VESANOID 10 mg, capsule molle

    The George Institute

    Oligometastatic solid cancer

    phase 2 small molecule active

    1 trial

  4. Valemetostat Tosylate, Valemetostat Tosylate

    The George Institute

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    phase 2 small molecule active

    1 trial

  5. Varnimcabtagene autoleucel, BENDAMUSTINE, FLUDARABINE, DEXCHLORPHENIRAMINE, CYCLOPHOSPHAMIDE, PARACETAMOL, TOCILIZUMAB, ALLOPURINOL

    The George Institute

    Acute lymphoid leukemia

    phase 2 small molecule active

    1 trial

  6. Venclyxto 100 mg film-coated tablets, Azacitidine Kabi 25 mg/mL powder for suspension for injection

    The George Institute

    acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  7. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    melanoma brain metastases

    phase 2 small molecule active

    1 trial

  8. ZEULIDE 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée, Elacestrant

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  9. Zercepac 150 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    cholangiocarcinoma or gallbladder carcinoma

    phase 2 small molecule active

    1 trial

  10. [18F]PI-2620

    The George Institute

    Down Syndrome, Alzheimer disease

    phase 2 small molecule active

    1 trial

  11. [18F]PI-2620

    The George Institute

    Down Syndrome., Alzheimer´s Disease.

    phase 2 small molecule active

    1 trial

  12. [18F]PI-2620

    The George Institute

    Progressive supranuclear palsy, Parkinson's disease

    phase 2 small molecule active

    1 trial

  13. florquinitau F-18, VIZAMYL 400 MBq/mL solution for injection, [18F]PI-2620

    The George Institute

    cognitive impairment

    phase 2 small molecule active

    1 trial

  14. lurbinectedin, JEMPERLI 500 mg concentrate for solution for infusion

    The George Institute

    Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy

    phase 2 small molecule active

    1 trial

  15. sodium chloride 9 mg/ml (0.9%) solution for injection, LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Merkel Cell Carcinoma

    phase 2 small molecule active

    1 trial

  16. 100 mg Delamanid

    Otsuka Beijing Research Institute

    Multidrug Resistant Tuberculosis

    phase 1 small molecule completed

    1 trial

  17. A Phase 1 study to test for safety and activity of an oral investigational drug, in patients with AML or other blood or bone marrow malignacies with an IDH1 mutation.

    The George Institute

    AG-120 is being investigated for the treatment of patients with advanced hematologic malignancies that are IDH1 mutation.

    phase 1 other active

    1 trial

  18. A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation

    The George Institute

    Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation

    phase 1 other active

    1 trial

  19. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  20. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  21. A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever (CCHF-NP-1)

    The George Institute

    Crimean Congo Hemorrhagic Fever

    phase 1 other active

    1 trial

  22. A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with relapse/refractory Acute Leukemia

    The George Institute

    Relapse/ refractory acute Leukemia

    phase 1 other active

    1 trial

  23. A Phase I, Open-label, Randomized, Active-Controlled, to Evaluate the Safety and Immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old Healthy Participants in Sweden.

    The George Institute

    Prevention of Cholera disease

    phase 1 other active

    1 trial

  24. A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment

    The George Institute

    Newly diagnosed and/or previously treated IDH1-mutated malignancies

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources